11月17日 - ** 医疗保健公司OrganonOGN.N股价盘前上涨4.65%至7.88美元
** OrganonOGN.N股价盘前上涨4.65%，报7.88美元。
** 两家公司的Poherdy是首个生物仿制药，可与罗氏ROG.S的Perjeta抗衡，用于治疗HER2阳性乳腺癌 - OGN
** 该公司称该药物可与其他疗法一起用于晚期或早期乳腺癌；Organon将在美国上市 - OGN
** 公司称 Poherdy 有心脏问题和先天缺陷警告；建议医生对患者进行监测
** 截至上次收盘，该股今年累计下跌约 50
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.